Listing 1 - 5 of 5 |
Sort by
|
Choose an application
Die Neuerscheinung beschäftigt sich mit der Patentierbarkeit von nanotechnologischen Erfindungen.
Choose an application
Die Entwicklung neuer Medikamente und deren Verbesserungen sind entscheidend, um deutliche Fortschritte in der Gesundheitsversorgung zu gewährleisten. Der Entwicklungsprozess ist lang und teuer, insbesondere der Aufwand,der betrieben werden muss,, um den hohen Regulierungsanforderungen gerecht zu werden. Im Gegensatz dazu verursacht die Nachahmung von Medikamenten vernachlässigbare Kosten und birgt deutlich weniger Risiken. Dies ist einer der Gründe, warum der Patentschutz für die die pharmazeutische Industrie von so großer Bedeutung ist. Trotz des bestehenden Patentsystems i
Drugs --- Drug development. --- Patent laws and legislation. --- Law and legislation. --- Law, Patent --- Patents --- Scientific property --- Industrial laws and legislation --- Industrial property --- Trade regulation --- Copyright --- Development of drugs --- New drug development --- Pharmacology --- Pharmacy --- Drug control --- Pharmaceutical industry --- Pharmaceutical policy --- Public health laws --- Law and legislation --- Development --- Laws and legislation --- Markenrecht --- Urheberrecht / Gewerblicher Rechtsschutz und Medienrecht --- Gewerblicher Rechtsschutz
Choose an application
The world increasingly faces the adverse impact of climate change. What role can intellectual property play to stimulate the necessary innovation and technology transfer? Providing an inventory of patent law, policy and information, including certain private initiatives, this thesis discusses issues at the crossroads of intellectual property and climate change, such as: compulsory licensing for climate change, patent offices
Patent laws and legislation. --- Patent licenses. --- Patents (International law) --- Technology transfer --- Environmental protection --- Climatic changes --- Climate change mitigation. --- Technological innovations --- Green technology. --- Geistiges Eigentum. --- Klimaänderung. --- Technologietransfer. --- Zwangslizenz. --- Law and legislation. --- Technology transfer. --- Lizenz --- Techniktransfer --- Technologieexport --- Wissens- und Technologietransfer --- Klima --- Klimawandel --- Klimaveränderung --- Klimawechsel --- Immaterialgut --- Eigentum --- Immaterialgüterrecht --- Antitrust law --- Industrial property --- Earth-friendly technology --- Environmental technology --- Technology --- Climate mitigation --- Climatic mitigation --- Mitigation of climate change --- Climate change mitigation --- Environmental law --- Liability for climatic change damages --- Patent laws and legislation (International law) --- International law --- Licenses (Patents) --- Patents --- Foreign licensing agreements --- License agreements --- Patent assignments --- Patent laws and legislation --- Law, Patent --- Scientific property --- Industrial laws and legislation --- Trade regulation --- Copyright --- Veränderung --- Mitigation --- Law and legislation --- Licenses --- Klimaveränderung --- Veränderung --- Technological innovations Law and legislation --- Markenrecht --- Urheberrecht / Gewerblicher Rechtsschutz und Medienrecht --- Gewerblicher Rechtsschutz
Choose an application
This book discusses the implications of the 2009 EU Commission’s Pharmaceutical Sector Inquiry on originator’s opportunities to apply Intellectual Property related measures in defending against generic competition. It argues that on the one hand recent developments in EU competition law do indeed impose potential limitations on an originator’s ability to block or delay generic market entry. On the other hand, the book calls for a differentiated assessment of the rather broad allegations made by the sector inquiry. The book thereby presents and thoroughly analyzes six key issues identified by the EU Commission in the inquiry’s final report: Blocking/defensive patenting, patent thickets, patent-related disputes and litigation, follow-on innovation, authorized generic entries and patent settlement agreements as well as interventions into generic marketing authorization. The analysis aims at reducing legal uncertainty by providing a clearer picture of legal boundaries between legitimate and problematic conduct under Arts. 101 and 102 TFEU. The book also puts the sector inquiry’s findings into a forward-looking perspective by highlighting industry trends with the potential to transform traditional originator and generic business models. The author studied economics and law, has gained substantial expertise about strategy development as a consultant to the pharmaceutical industry and currently leads strategic research management at a large life sciences public research organization in Germany.
Drugs --- Generic drugs --- Antitrust law --- Law and legislation --- Generic equivalents (Drugs) --- Generics (Drugs) --- Generic products --- Generic substitution --- Wettbewerbsrecht --- Handels- und Wirtschaftsrecht --- Kartellrecht
Choose an application
Defining the true meaning of the acronym FRAND reminds of the parable of two political parties arguing before the elections: who is right and who is wrong, although they both know that there is no such thing as one truth and most utterly it depends on the individual perspective. Given the very substantial legal and business concerns involved within the telecommunication standardization environment, the conflicts what FRAND terms and conditions means seem to be unavoidable.
Patent licenses --- Patent suits --- Antitrust law --- Global system for mobile communications --- Treaty Establishing the European Economic Community --- Fair, reasonable, and non-discriminatory terms --- GSM communications --- Cell phone systems --- Context-aware computing --- Patent litigation --- Patent laws and legislation --- Licenses (Patents) --- Patents --- Foreign licensing agreements --- License agreements --- Patent assignments --- Licenses --- Markenrecht --- Urheberrecht / Gewerblicher Rechtsschutz und Medienrecht --- Gewerblicher Rechtsschutz
Listing 1 - 5 of 5 |
Sort by
|